• Login
    View Item 
    •   DSpace Home
    • Centro Académico de Salud (CAS)
    • Hospital Universitario Austral -HUA-
    • Investigación Aplicada
    • View Item
    •   DSpace Home
    • Centro Académico de Salud (CAS)
    • Hospital Universitario Austral -HUA-
    • Investigación Aplicada
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Ombitasvir / paritaprevir / ritonavir / dasabuvir  ±  ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina .

    Thumbnail
    View/Open
    IA - Mendizabal (114.0Kb)
    Date
    2017-03-29
    Author
    Mendizabal, Manuel.
    Haddad, Leila.
    Gallardo, Patricia.
    Ferrada, Alejandro.
    Soza, Alejandro.
    Adrover, Raul.
    Aravena, Edmundo.
    Metadata
    Show full item record
    Abstract
    Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real-world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child-Pugh B at baseline and one patient died due to multi-organ failure. Follow up HCV-RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child-Pugh A cirrhosis in non-European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child-Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region.
    URI
    https://riu.austral.edu.ar/handle/123456789/819
    Collections
    • Investigación Aplicada

    xmlui.dri2xhtml.structural.info-link
    Licencia Creative Commons
    xmlui.dri2xhtml.structural.contact-link1 - xmlui.dri2xhtml.structural.contact-link2
    xmlui.dri2xhtml.structural.info-link2
     

     


    xmlui.dri2xhtml.structural.info-link
    Licencia Creative Commons
    xmlui.dri2xhtml.structural.contact-link1 - xmlui.dri2xhtml.structural.contact-link2
    xmlui.dri2xhtml.structural.info-link2